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Abstract
Background: The reduced mortality rate from breast carcinoma among women offered screening
mammography is demonstrated after 15–20 years of follow-up. However, the assessment of 5-year
overall and event-free survival could represent an earlier measure of the efficacy of mammography
screening program (MSP).
Methods: All cases of breast cancer diagnosed in the Province of Modena between years 1996 and
2000 in women aged 50 to 69 years, were identified through the Modena Cancer Registry (MCR).
Stage of disease and treatment information were obtained from clinical records. All the events
occurring up to June 30, 2003 were retrieved by experienced monitors. Five-year overall and
event-free survival were the principal end-points of the study.
Results: During a 5-year period, 587 primary breast cancers were detected by the MSP and 471
primary breast cancers were diagnosed out of the MSP. The screen-detected breast cancers were
smaller, more likely node negative, with low histological grade, low proliferative activity and
positive receptors status. Furthermore, the breast cancer diagnosed through the MSP more
frequently received a conservative surgery. The 5-year survival rate was 94% in the screen-detected
group, versus 84% in the other group (p = 0.0001). The rate of 5-year event-free survival was 89%
and 75% for the MSP participants and not participants, respectively (p = 0.0001).
Conclusions: Our data confirm a favourable outcome of screen-detected breast cancers in terms
of five-year overall and event-free survival, which reflect the good quality assurance parameters of
the MSP. Finally, a cancer registry should be implemented in every area covered by screening
programs.
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Background
Breast cancer is the most common malignancy in women,
both in the developed and developing world, with annual
incidence rates ranging from 11.8 per 100,000 in eastern
China to 86.3 per 100,000 in North America[1]. During
recent decades the incidence of breast cancer has increased
in Western Europe and the United States, while the mor-
tality decreased[2,3]. Part of the increase in incidence
reflects the success of breast cancer screening programs[4].
There is sufficient evidence from randomized trials that
inviting women 50–69 years of age to be screened with
mammography will eventually reduce their mortality
from breast cancer. The first randomized clinical trial per-
formed in New York during the 1960s evaluated the value
of "early detection" by physical examination and mam-
mography[5], while the Swedish trials, during the 1970s
and 1980s (Malmo, Two-County, Stockholm and Gote-
borg) used only mammography to find out the independ-
ent value of this modality [6-9]. A recent review
performed by a committee confirmed their previous
results [10]. Even another randomized trial in the United
Kingdom (Edinburgh) gave the same results[11]. Mam-
mography screening reduces breast cancer mortality of
invited women by 20% to 30% in comparison with con-
trols. Mammography screening makes it possible to detect
breast cancer at a subclinical or non-palpable stage. Early
detection of such small tumours by screening shows a
positive effect on survival because of overall decreased
mortality from breast cancer [12-14]. Even after a follow-
up period as long as 17 years the expected rate of mortality
from breast cancer is reduced[15]. In Modena, Italy, a
population-based mammography screening for breast
cancer was begun in 1995, providing a biennial screening
to women aged 50 to 69 years. However, since the effect
on breast cancer mortality will only become evident in the
long term, monitoring the early outcomes seemed to us
essential in the early phases for early evaluation of the effi-
cacy of the screening program. In fact, several studies have
shown that the interval from initial diagnosis to recur-
rence is a relevant prognostic factor [16,17], since patients
with early recurrence tend to do worse than those with late
relapse [18].
In the current study we report the results of an exhaustive
review of all breast cancers diagnosed between October
1995 and December 2000 in the Province of Modena, in
women 50–69 years of age, assessing the rates of small
tumors, the patterns of care and the relapse-free, event-
free and 5 years survivals in women exposed to screening
and in women diagnosed over the same time-interval out
of screening.
Methods
Data sources
In October, a population-based mammography screening
program (MSP) began in the Province of Modena, one of
the nine provinces of the Emilia-Romagna region (located
in northern Italy). On december 1996, the population of
Modena was 613,625, which by the end of 2000 had
increased to 632,626, with a density of 235 inhab./sq.km.
Out of this population, 80,210 were healthy women, aged
50–69 years. Briefly, all the asymptomatic female resi-
dents in the Province of Modena aged 50–69 years were
invited to participate in a biannual bilateral two-view
screening mammogram, with no direct financial charge to
the participant. Women already affected by breast cancer
were not invited. From 31st  December, 1999 to 31st
December, 2000, 48,928 women aged 50–69 years partic-
ipated in the screening mammography, with an adhesion
rate of 61.3%. Up to 31st December, 2000, 43,479 women
adhered to the program (adhesion rate of 65.9%).
Subjects
All the patients with an age ranging from 50 to 69 years
diagnosed with breast cancer in the period 1996–2000
were selected from the Modena Cancer Registry (MCR),
which has operated since 1988 and collects all new cases
of cancers occurring in residents in the Province of
Modena. A cross linkage between data from MSP and
MCR allowed the identification of cases with invasive or
in situ breast cancer diagnosed between 1st January, 1996
and 31st December, 2000 who did and did not the MSP.
All breast cancer cases were identified as International Clas-
sification of Disease (9th revision) rubric 174. For every case,
data on histology, staging at presentation (based on the
2003 UICC-TNM classification [19] and treatment were
obtained from clinical records. All the events (local or dis-
tant recurrence, either second breast or non-breast
tumours and deaths from breast cancer or from any other
cause) that occurred among these women through during
Table 1: Mean follow-up between the two groups and relative differences between patients at every stage
Stage Distribution of those 
exposed to screening
Time of mean follow-
up in thoxe exposed 
to screening (months)
Distribution in non 
screen-detected
Time of mean follow-
up in non-screen-
detected (months)
Differences between 
mean follow-up 
(months)
I 357 54.13 199 54.01 0.12
II 115 51.39 156 48.49 2.9
III 2 50.58 30 49 1.56
IV 8 32.57 26 36.32 -3.75BMC Cancer 2006, 6:17 http://www.biomedcentral.com/1471-2407/6/17
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the follow-up were retrieved by experienced clinical docu-
mentation clerks with active follow-up strategies.
Statistical analysis
Overall survival was defined as the time from surgery until
death from any cause, and cancer-free survival was
defined as the time from surgery until the appearance of
the first recurrence of cancer, a second cancer, or death
from any cause. Survival was estimated by the Kaplan-
Meier method, and any differences in survival were evalu-
ated with a stratified log-rank test.
The Statistical Package for Social Sciences (version 10,
SPSS®) was used for all calculations. Differences were con-
sidered to be statistically significant when the P value was
0.05 or less. All statistical tests were two-sided.
The Cox proportional hazards regression model was used
in multivariate analysis, to determine whether the identi-
fied risk factors independently influenced survival rates.
The co-variates selected were: modality of detection
(screening vs. non screening), TNM stage (I vs others),
chemotherapy (performed or not performed) and hormo-
nal treatment (performed or not performed). Hazard
ratios (HR) and 95% exact mid-P confidence intervals
(CI) were calculated and the Wald method was used for
the significance test.
As shown in table 1, screen-detected breast cancers had a
more favorable stage at diagnosis than the non-screen-
detected breast cancer. Lead-time bias (i.e., the time inter-
val between cancer detection and death being longer in
screen-detected than in non-screen-detected breast can-
cers, due to early diagnosis) and length bias (i.e., screen-
ing being more likely to detect breast cancers with long
preclinical phases than rapidly progressive cancers) are
two potential sources of bias in the evaluation of the effec-
tiveness of breast cancer screening. In order to limit the
effect of lead-time and length bias, information on stage
distribution was used as follows:
5-year event-free survival Figure 1
5-year event-free survival. 5-year event-free survival values between MSP participants and non-participants were equal to 89% 
and 75% respectively (Log Rank = 19.99). [  = MSP participants;   = MSP non-participants]
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and
ci,s = xi,s - ts
where ts is the mean difference in follow-up time duration
between the two groups at stage s, for i from 1 to Nsd and
for j from 1 to Nnsd, xi,sd and xj,nsd are durations of follow-
up for each woman at each stage in each group and
Nsdand Nnsd are the population size of screen and not
screen-detected groups. Then, the correct follow-up time
(ci,s) is obtained by subtracting the stage-specific differ-
ence from the follow-up time in the screen-detected
group.
Results
Proportion of cancers detected by the MSP
Between 1st January, 1996 and 31st December, 2000, 587
(55%) new breast cancers were detected among women
aged 50–69 attending the MSP. The detection rate was
10%0 (428) in the first, 6.5%0 (152) in the second and
7.9%0 (7) in the third round. The recall rate was higher at
the first round (8.2%) than in the second (6.4%) and the
third round (4.5%). In the same time frame 471 (45%)
breast cancers were diagnosed out of the MSP. Out of
these cases, 337 had had a carcinoma before they were
first invited by the MSP, 56 arose in women excluded by
the screening program since they had a mammography in
the last year and 78 arose in women that refused to partic-
ipate in a screening program. Out of 587 screen-detected
breast cancers, which also include 34 interval cases devel-
oped in women who had participated in the screening
program in the past, 482 (82%) were infiltrating and 105
(18%) were in situ carcinomas. Out of the 471 breast can-
cers non-screen-detected, 429 (91%) were infiltrating and
42 (9%) were in situ carcinomas. The median age at diag-
t
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5-yearOS Figure 2
5-yearOS. 5-year OS between MSP participants and non-participants was equal to 94% and 84% respectively (Log Rank = 14.99). 
[  = MSP participants   = MSP non-participants]
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nosis was 60 years in both groups. Furthermore the
median age at diagnosis in women of 50–69 years in the
pre-screening era was 60.5. The age-specific rate of inva-
sive cancers diagnosed each year increased from 304.7 per
100.000 in 1996 to 380.3 per 100.000 in 2000. The age-
specific rate of in situ carcinoma diagnosed each year
increased from 31.9 per 100.000 in 1996 to 49.7 per
100.000 in 2000. As already reported [20] the incidence
rates increased only in the age group 50–69 years.
Prognostic factors
The clinical pathological factors for the two cohorts are
shown in Tab. 2. There were significant differences
between the screen-detected and non-screen-detected can-
cers with respect to clinical/pathological prognostic fac-
tors (all P < 0.0001). The screen-detected tumours were
smaller sized, were more likely to be grading I-II, patho-
logically confirmed node negative disease and low prolif-
erative activity. There was also a significant difference in
the percentage in women with positive hormonal status
(84% and 73%, respectively; P = 0.02).
Concerning the characteristics of interval cancers, they
had a mean size of 18 mm, the nodal status and the hor-
monal receptors were positive in 24% and 70% of cases,
respectively, and the proliferative activity was high in 34%
of tumours. Finally the tumours was poorly differentiated
(GIII) in 45% of cases.
Survival data
The median follow-up was 52 months in both groups,
with a 25% of patients followed for more than 66 months.
Survival data were evaluated only for invasive cancers, i.e.
for 482 patients exposed to screening and 429 in the non-
screen exposed group. Six (1%) and thirty-nine (9%)
patients were lost at the follow-up in the study and con-
Table 3: Outcome and type of events that occurred in women, aged 50–69 years, with breast cancer diagnosed between 1996 and 2000 
in the Province of Modena by screening status
Screen-detected n(%) Non screen-detected n(%) p-value
EVOLUTION < 0.0001
Alive 454 (94) 330 (77)
Dead 22 (5) 60 (14)
Lost at follow-up 6 (1) 39 (9)
RECURRENCE 33 (6.8) 42 (9.7) 0.02
Local 8 (1.6) 12 (2.8)
Distant 25 (5.1) 30 (6.9)
SECOND BREAST CANCER 1 (0.2) 9 (2) 0.02
BREAST CANCER SPECIFIC 
DEATH
20 (4) 41(9) <0.05
OTHER SECOND 
MALIGNANCIES
15 (3) 16 (4) NS
DEATH FROM OTHER CAUSES 2 (0.4) 19 (4.4) <0.0001
TOTAL EVENTS 48(9.9) 83(19) <0.0001
Table 2: Prognostic factors' distribution among women exposed to screening and non-screen-detected invasive breast cancers
Prognostic Factor Exposed to screening n(%) Non-screen-detected n(%) p-value
Tumour size (mm.)
1–10 231 (48) 102 (24)
11–20 218 (45) 167 (39)
21–50 33 (7) 140 (32)
> 50 -- 20 (5)
Mean Size 13 19 < 0.0001
Positive Nodal Status 93 (19) 165 (38) < 0.0001
Positive Hormonal Status 403 (84) 313 (73) < 0.05 (0.02)
Proliferative Activity < 0.0001
LOW 343 (74) 236 (61)
HIGH 118 (26) 150 (39)
Grading <0.0001
1 108 (25) 76 (21)
2 209 (49) 143 (40)
3 113 (26) 142 (39)BMC Cancer 2006, 6:17 http://www.biomedcentral.com/1471-2407/6/17
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trol group, respectively. At time of last follow-up 22
women had died in the screen-detected (20 for breast can-
cer and 2 for other causes) and 60 in the non-screen-
detected group (19 for breast cancer recurrences and 41
for others causes). The overall survival rates in the two
groups differed significantly on the basis of the stratified
log-rank test. As expected, the majority of deaths occurred
in patients with breast cancer non- screen-detected (p <
0.0001).
At the time of the present analysis a total of 131 events
were registered, including 75 recurrences, 10 second
breast cancers, 25 different second malignancies, and 21
deaths not related to breast cancer or its treatment. We
observed 48/482 (9.6%) events in the screen-detected
group and 83/429 (22.6%) in the non-screen-detected
group, with a statistically significant difference (p <
0.0001). A significant difference was also observed in the
number of disease recurrences (33 in the screen-detected
group and 42 in the non-screen-detected group, p = 0.02)
and of second breast cancers (1 vs 9, p = 0.02) (Tab. 3). As
a result of these differences, the 5-year event-free survival
was equal to 89% and 75% among the MSP participants
and non-participants, respectively (p = 0.0001) (Fig. 1).
The 5-year overall survival was 94% in the screen-detected
group and 84% in the non screen-detected group and this
difference was statistically significant (p = 0.0001) also
after adjustment for calculated lead-time and length
biases (Fig. 2). In both analyses the interval cancers were
also included. In univariate analysis of overall survival,
factors associated with a good prognosis were: detection
by screening (p < 0.0001), TNM stage I (p < 0.0001),
chemotherapy (p < 0.0001) and hormonal therapy (p =
0.25). In a multivariate analysis diagnosis through the
MSP, TNM stage I and hormonal treatment remained an
independent prognostic value (Tab. 4).
The 5-year estimated survival rates were 98% and 96% =
0.8 (Fig. 3a) for T1a-b stage, respectively in the screen-
detected and non-screen-detected group. Also for T1c
stage, the 5-year estimated survival rates were similar in
the two group (93% vs. 89%, respectively = 0.3). (Fig. 3b).
No significant difference in the 5-year survival rates of the
two stages was found between the two groups. This find-
ing shows that the prognosis of small tumours is not
influenced by the modality of diagnosis.
However, considering node-negative cases as a whole, the
5-year survival rates were 95% in the screen-detected
group and 91% in the non-participants to the MSP (Fig.
4). The difference between the two groups was statistically
significant (p = 0.04) depending on the higher rate of
smaller tumors in the MSP group. Also the 5-year survival
rates for the node-positive breast cancers showed a signif-
icant difference between the two groups (87% in the
screen-detected breast cancer and 73% in the non-screen-
detected (p = 0.02)(Fig. 5).
Discussion
The present study has shown that breast cancers detected
through MSP are usually diagnosed at an early stage and
are associated with a very favourable behaviour of the dis-
ease and an excellent prognosis, in terms of 5-year event-
free survival and Overall Survival. Moreover, the study has
also suggested that a population-based cancer registry is a
relevant tool in the evaluation of a cancer screening pro-
gram.
The decision to offer regular mammographic screening is
based on the demonstration of reduced breast cancer-spe-
cific mortality in prospective randomized clinical trials
[21-24]. In the randomized trials of breast screening, com-
parison of the prognostic profile of cancers detected in the
invited as compared with the control groups has identi-
fied surrogate intermediate endpoints associated with the
mortality reductions in those trials. These endpoints
include such factors as the proportion of cancers smaller
than 15 mm diameter or absence of lymph node involve-
ment at diagnosis. It has been suggested that these inter-
mediate endpoints might be useful to predict the
likelihood that an organized breast screening program
will achieve its mandate of mortality reduction on a pop-
ulation basis [25]. The prognostic profile of screen-
detected breast cancer within the MSP not only meets the
Table 4: Factors with independent prognostic value of survival
Factor HR 95%CI P value
DIAGNOSIS INSIDE MSP
No 1(referent)
Yes 0.58 0.36–0.92 0.023
STAGE
II,III, IV 1(referent)
I 0.16 0.08–0.30 0.0001
HORMONAL THERAPY
No 1(referent)
Yes 0.50 0.32–0.78 0.002BMC Cancer 2006, 6:17 http://www.biomedcentral.com/1471-2407/6/17
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targets derived from the randomized trials, but also dem-
onstrates a significant advantage in terms of initial ther-
apy and event-free survival when compared to other
breast cancers diagnosed in the same geographically-
defined population over the same time period.
In fact, since the beginning of the organized mammogra-
phy screening program, an increasing proportion of
women with newly diagnosed breast cancer each year (76
in 1996, 100 in 1997, 131 in 1998, 173 in 1999, 175 in
2000) have been MSP participants. The cancers diagnosed
in women within four years of the screening program
were histologically more favourable (GI-II, hormonal
receptors positive, low proliferative activity), smaller (13
mm vs 19 mm) and less likely to have spread to axillary
lymph nodes compared to breast cancer diagnosed out of
the screening over the same time frame.
Since the crude breast cancer-specific mortality rate can-
not be used for an immediate evaluation of the impact of
screening mammography, we have used Event-Free Sur-
vival at 5 years as a measure of success of the MSP. We
considered as events local or distant recurrence of breast
cancer, second breast cancer, second cancer other than
breast, and death from any cause. The rate of recurrences
and second breast cancers, but not of other second malig-
nancies or deaths, was significantly lower in the screen-
detected group. As a consequence we observed a statisti-
cally significant and clinically meaningful 14% improve-
ment in the 5-year event-free survival of women
diagnosed by the MSP compared with those diagnosed
out of the screening (89% vs. 75%). A difference was also
observed in the subset of node negative tumors, where the
5-year survival rates are 95% in the screen-detected group
and 91% in the non participants to the MSP. These results
5-year survival of pT1a+b (3a) and pT1c (3b) Figure 3
5-year survival of pT1a+b (3a) and pT1c (3b). 5-year OS values of pT1a+b (a) and pT1c (b) breast cancers between MSP partici-
pants and non-participants were equal to 98% and 96% (Log Rank = 0.76) respectively (a) and 93% and 89% (Log Rank = 1.57) 
respectively (b). [  = MSP participants;   = MSP non-participants]
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correlate with data from a recent study performed by Joen-
suu, in which a 5-year survival rate of 97% was observed
in women with node negative tumors [26]. In addition
Joensuu and colleagues found a significant correlation
between tumor size and prognosis. In fact, the 20-year sur-
vival rate was 93% for tumors of one cm or less, and only
75% for tumors of more than one cm in size. On the basis
of that study we can predict that the excellent 5-year sur-
vival rate of 94% observed for tumors detected by the MSP
(48% of which have a maximum diameter of one centim-
eter or less) will translate in a long term (i.e. 10 years) sur-
vival exceeding 90%.
Welch et al. [27] and Baum [28], state that 5-years survival
rate is not sufficient to demonstrate the effectiveness of a
screening program This period is considered too brief to
by-pass the lead-time bias, that is the earlier detection of a
breast cancer, which increases the survival from the time
diagnosis to the time of death, without influencing the
natural history of the disease. Calculating the 5-year sur-
vival rates after adjustment for lead-time and length bias
confirmed our finding of a better prognosis of screen-
detected cancers. The analysis of mean follow-up duration
for every stage showed a superimposable period between
the two groups, particularly for stage I BC, which were the
most frequently detected cancers in the screen-detected
group. Although the MSP seem sufficiently cost-effective,
we have to realize that 29% of the tumours were not
detected by screening. In fact, the MSP not only missed a
small number of interval cancers (n = 34) but also did not
cover the cancers occurring in patients excluded for
screening because of a recent mammogram outside the
MSP (n = 56) and in women who refused to participate in
the screening program. Our results confirm that the char-
acteristics of interval cancers are intermediate, between
screen and non-screen detected tumors, in terms of size
5-year survival in N- BC Figure 4
5-year survival in N- BC. 5-year OS values of N- breast cancers between MSP participants and non-participants were equal to 
95% and 91% respectively (Log Rank = 5.74). [  = MSP participants;   = MSP non-participants]
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(17.7 mm), nodal status (24% positive), hormonal recep-
tors (70% positive) and high proliferative activity (34%).
Overall the sensitivity of our screening program, consid-
ered as a proportion of screen-detected cancers in all can-
cers diagnosed in the target population was 55%.
However, the performance of the MSP compares favoura-
bly with the recommendations of the European Commis-
sion for quality assurance in mammography screening
[29], which indicate a good detection rate at the first
round when it is more than 3.5 fold of the incidence rate
before the screening (2.6%0) and more than 1.5 fold at
the subsequent rounds. Finally, we exclude that a class
bias could have influenced our results since the number of
women belonging to a low social class in the province of
Modena according to the Statistic Service is very low
(0.83%). Even though there is no direct information on
social class status of population invited to the MSP, in an
interview performed for a cervical screening program in
Modena province, no differences between women belong-
ing to a high or low social class in terms of participation
to the study were found. In fact almost all women partici-
pated in the study, whereas in many other countries only
women from the higher socioeconomic and educational
strata are more likely to accept the invitation to screen and
to participate in other health-promoting patterns of
behaviour [30].
Our data clearly show that the major cause for the decreas-
ing breast cancer mortality is the smaller tumour size,
associated with the earlier detection by the MSP. Moreo-
ver, the chemotherapy was not retained as an independ-
ent prognostic factor, confirming that the magnitude of
impact of chemotherapy is very likely less relevant com-
pared to the effect of early detection. Despite that, in our
5-year survival in N+ BC Figure 5
5-year survival in N+ BC. 5-year OS values of N+ breast cancers between MSP participants and non-participants were equal to 
87% and 73% respectively (Log Rank = 5.02). [  = MSP participants;   = MSP non-participants]
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series of screen-detected breast cancers, a very high rate of
patients were treated with chemotherapy, even if the most
used regimen was CMF.
Finally, we would remark that our study was made possi-
ble and facilitated only by the existence of a population-
based cancer registry in the area. Through the registry we
recognized all new cases of cancers in women aged 50–69
years and achieved information on follow-up status. We
consider a cancer registry an important tool for an ade-
quate monitoring of the screening programs.
Conclusion
In conclusion, our data show the effectiveness of the MSP
in terms of early diagnosis, more favorable behaviour of
the tumor and better prognosis, even if only 65% of the
age-eligible female were partecipating in this program in
1996–2000. This analysis has pointed out the need and
potential value of substantially increasing recruitment to
the MSP to 70% or more, as achieved in other geographic
areas.
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